Crystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
Develops next-generation bispecific ADCs for cancer treatment
Develops therapeutics for pulmonary diseases, specifically COPD
Develops medicines targeting historically undruggable protein targets in cancer